Zacks Research Analysts Increase Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD - Free Report) - Research analysts at Zacks Research boosted their FY2026 earnings estimates for Ironwood Pharmaceuticals in a research report issued on Wednesday, January 8th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of $0.44 for the year, up from their previous estimate of $0.43. The consensus estimate for Ironwood Pharmaceuticals' current full-year earnings is $0.08 per share.

Separately, StockNews.com downgraded shares of Ironwood Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Tuesday, November 12th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $10.40.

Ironwood Pharmaceuticals Stock Performance

Shares of NASDAQ:IRWD traded down $0.40 on Monday, hitting $3.56. The stock had a trading volume of 719,246 shares, compared to its average volume of 2,159,146. Ironwood Pharmaceuticals has a twelve month low of $3.06 and a twelve month high of $15.70. The firm's 50 day moving average price is $4.06 and its 200-day moving average price is $4.73. The company has a market capitalization of $569.70 million, a price-to-earnings ratio of -118.67 and a beta of 0.34.

Ironwood Pharmaceuticals (NASDAQ:IRWD - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts' consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative return on equity of 0.96% and a negative net margin of 0.65%. The business had revenue of $91.60 million for the quarter, compared to analyst estimates of $91.22 million. During the same quarter in the prior year, the firm earned $0.12 EPS. The firm's quarterly revenue was down 19.4% on a year-over-year basis.

Insiders Place Their Bets

In other news, CFO Sravan Kumar Emany sold 11,001 shares of the company's stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total value of $44,884.08. Following the completion of the sale, the chief financial officer now directly owns 309,572 shares of the company's stock, valued at $1,263,053.76. This represents a 3.43 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 12.90% of the company's stock.

Institutional Trading of Ironwood Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Pacer Advisors Inc. grew its position in shares of Ironwood Pharmaceuticals by 26.6% in the 3rd quarter. Pacer Advisors Inc. now owns 11,279,822 shares of the biotechnology company's stock valued at $46,473,000 after purchasing an additional 2,372,183 shares during the period. State Street Corp boosted its position in Ironwood Pharmaceuticals by 7.3% during the 3rd quarter. State Street Corp now owns 9,919,865 shares of the biotechnology company's stock worth $40,870,000 after acquiring an additional 677,024 shares during the last quarter. Renaissance Technologies LLC boosted its position in Ironwood Pharmaceuticals by 20.7% during the 2nd quarter. Renaissance Technologies LLC now owns 8,571,898 shares of the biotechnology company's stock worth $55,889,000 after acquiring an additional 1,472,097 shares during the last quarter. Armistice Capital LLC boosted its position in Ironwood Pharmaceuticals by 44.4% during the 2nd quarter. Armistice Capital LLC now owns 7,800,000 shares of the biotechnology company's stock worth $50,856,000 after acquiring an additional 2,400,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Ironwood Pharmaceuticals by 23.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,904,271 shares of the biotechnology company's stock worth $7,846,000 after acquiring an additional 364,841 shares during the last quarter.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.